Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Chan

Showing results (161-170 of 263) with videos related to

Pageof 27
Sort By:
The American Journal of Surgical Pathology|December 9, 2021
Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic DiseaseEmily Chan, Bradley A Stohr, Robert S Butler, et al.
Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Journal of Innate Immunity|October 1, 2023
Emerging Roles of cGAS-STING Signaling in Mediating Ocular InflammationLinbin Zhou, Bo Man Ho, Hoi Ying Emily Chan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 24, 2016
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancerEmily Chan, Lori R Arlinghaus, Dana B Cardin, et al.
The American Journal of Surgical Pathology|June 13, 2025
Serous Borderline Tumors of the Testis and Paratestis: A Clinicopathologic Study of 19 Tumors Emphasizing Morphologic Spectrum and Clinical OutcomeAli Shahabi, Aleksei Konstantinov, Jesse K McKenney, et al.
The Prostate|September 19, 2022
Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysisEmily Chan Brodowsky, Akshay Sood, Mohit Butaney, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Cell Reports|August 16, 2018
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 AcetylationRyan Raisner, Samir Kharbanda, Lingyan Jin, et al.
Clinical Colorectal Cancer|May 22, 2026
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal CancerLisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, et al.
Cancer Discovery|December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790MHo-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Pageof 27

Showing results (161-170 of 263) with videos related to

Sort By:
Pageof 27
The American Journal of Surgical Pathology|December 9, 2021
Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic DiseaseEmily Chan, Bradley A Stohr, Robert S Butler, et al.
Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Journal of Innate Immunity|October 1, 2023
Emerging Roles of cGAS-STING Signaling in Mediating Ocular InflammationLinbin Zhou, Bo Man Ho, Hoi Ying Emily Chan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 24, 2016
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancerEmily Chan, Lori R Arlinghaus, Dana B Cardin, et al.
The American Journal of Surgical Pathology|June 13, 2025
Serous Borderline Tumors of the Testis and Paratestis: A Clinicopathologic Study of 19 Tumors Emphasizing Morphologic Spectrum and Clinical OutcomeAli Shahabi, Aleksei Konstantinov, Jesse K McKenney, et al.
The Prostate|September 19, 2022
Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysisEmily Chan Brodowsky, Akshay Sood, Mohit Butaney, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Cell Reports|August 16, 2018
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 AcetylationRyan Raisner, Samir Kharbanda, Lingyan Jin, et al.
Clinical Colorectal Cancer|May 22, 2026
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal CancerLisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, et al.
Cancer Discovery|December 12, 2012
Noncovalent wild-type-sparing inhibitors of EGFR T790MHo-June Lee, Gabriele Schaefer, Timothy P Heffron, et al.
Pageof 27